Sio Gene Therapies, Inc. (SIOX)
| Market Cap | 25.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68.42M |
| Shares Out | 73.98M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,378 |
| Open | 0.341 |
| Previous Close | 0.353 |
| Day's Range | 0.340 - 0.360 |
| 52-Week Range | 0.230 - 2.655 |
| Beta | 1.61 |
| Analysts | Sell |
| Price Target | 5.10 (+1,356.3%) |
| Earnings Date | Aug 9, 2022 |
About SIOX
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Th... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SIOX stock is "Sell." The 12-month stock price forecast is 5.1, which is an increase of 1,356.31% from the latest price.
News
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022.
Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
Sio Gene Therapies Inc (NASDAQ: SIOX) will terminate its licensing agreement with the University of Massachusetts to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and ...
Sio Gene Therapies Provides Corporate Update
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts -Company has engaged SVB Securities to advise it on a range of strategic alterna...
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...
Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition
Sio Gene Therapies Inc SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson's disease. [LIVE NOW ON YOUTUBE] C...
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of...
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, resp...
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Gran...
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson's...
- Completed three successful GMP campaigns using suspension-based manufacturing process - All batches achieved target titers and have successfully completed fill and finish - Qualified Person (QP) certi...
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in P...
- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations - Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases
Sio Gene Therapies Announces Reorganization of R&D Group
Two new executive positions created in connection with departure of R&D Head Two new executive positions created in connection with departure of R&D Head
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene ...
NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...
Sio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action
Sio Gene Therapies Inc (NASDAQ: SIOX) has announced interim data from its Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis. GM...
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-...
NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...
UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss new...
Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss new...
Sio Gene Therapies to Participate in Upcoming Conferences
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve t...
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2...
- Study has now enrolled a total of nine patients across low-dose and high-dose cohorts - On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 coh...
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway
Are Options Traders Betting on a Big Move in Sio Gene Therapies (SIOX) Stock?
Investors need to pay close attention to Sio Gene Therapies (SIOX) stock based on the movements in the options market lately.
Sio Gene Therapies' GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF
Sio Gene Therapies Inc (NASDAQ: SIOX) has announced new biomarker data from Phase 1/2 study of AXO-AAV-GM1, an adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis. T...
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...
Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of G...
NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transfor...
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...